Meeting
2017 ASCO Annual Meeting
The potential clinical impact of pre-emptive screening of multiple polymorphisms in gene-encoding DPD on patients candidate for fluoropyrimidine based-chemotherapy: An experience of the Northern Italy Cancer Centre.
Authors
Francesco Iachetta
Medical Oncology Unit, Clinical Cancer Centre, Arcispedale Santa Maria Nuova – IRCCS, Reggio Emilia, Italy
Francesco Iachetta , Angela Damato , Candida Bonelli , Alessandra Romagnani , Maria Banzi , Davide Nicoli , Enrico Farnetti , Bruno Casali , Carmine Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2567)
DOI
10.1200/JCO.2017.35.15_suppl.2567
Abstract #
2567
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy: A case-control study in a Northern Italy Cancer Centre.
First Author: Francesco Iachetta
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz
Poster
2020 ASCO Virtual Scientific Program
Prophylactic dihydropyrimidine dehydrogenase (DPYD), and reactive cytidine deaminase (CDA) testing is feasible and reduces severe toxicity in Irish patients receiving 5-fluorouracil (5-FU) based chemotherapy.
First Author: Jake Murphy
Poster
2016 Gastrointestinal Cancers Symposium
Germline pharmacogenomics in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
First Author: Moh'd M. Khushman